Before you can achieve a high level of operational excellence, you've got to nail down predictability, says Dr. Patrick Yang, Genentech's Executive VP for Products Operations. Too many companies aim high at the start of operational excellence initiatives, Yang says, at the expense of planned, predictable operations.
The past few weeks have seen a dramatic increase in mergers and acquisitions, with the generic drug manufacturer Teva buying Barr and Roche bidding for Genentech. Frost & Sullivan analyst Rhenu Bhuller, pharma industry VP, shared these perspectives. Click here to watch brief video.
Once again, had to miss the best part of this presentation, but did hear Robert Bottone of Genentech discuss the problem that some managers in biopharm and pharma have with Operational Excellence. Many of them still expect “silver bullet’ solutions.
Installment 3 (and, no, sorry, that is not me) ISPE announced the Facility of the Year 2007 winners at its annual meeting in Las Vegas. One of our competitors is part of this competition, but there is room for many awards in this sphere.
Pharmaceutical companies are constantly being berated/fined for overzealous salespeople selling drugs off label to doctors/pharmacies. In the recent case of Genentech's Avastin, the shoe appears to be on the proverbial other foot. Earlier this month, Genentech made the decision to restrict the availability of Avastin to compounding pharmacies.
Boehringer Ingelheim narrowly beat out Genentech and Amgen in Science's annual survey of top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. The survey was based on industry responses by participants to whom they regarded as the best, average and worst employers in the field.